阿德福韦酯联合拉米夫定治疗乙型肝炎DNA阳性肝硬化疗效观察

Efficacy of Adefovir Dipivoxil and Lamivudine on Treatment of Hepatitis B Related Cirrhosis with DNA Positive

目的:探讨阿德福韦酯联合拉米夫定治疗HBV DNA阳性乙型肝炎肝硬化的疗效。方法:46例HBV DNA阳性乙肝肝硬化患者随机分为对照组及观察组。在保肝等对症治疗基础上,观察组22例患者联用阿德福韦酯与拉米夫定,对照组24例患者予阿德福韦酯,总疗程均为48周。结果:在治疗12周后,观察组与对照组HBV DNA转阴率分别为54.5%、20.8%(P<0.05),ALT复常率分别为63.6%、33.3%(P<0.05)。治疗24周、48周后上述指标无统计学差异。两组患者未见明显药物不良反应。结论:阿德福韦酯联合拉米夫定治疗HBV DNA阳性乙型肝炎肝硬化起效快,降低病毒载量疗效佳,安全性好。

Objective：To investigate efficacy of adefovir dipivoxil and lamivudine on treatment of hepatitis B related cirrhosis with DNA positive.Methods：46 patients with liver cirrhosis and HBV DNA positive were randomly divided into the control group and observation group.Based on the symptomatic treatment,the observation group（22 patients） were treated with adefovir dipivoxil combined with lamivudine,and the control group（24 patients） were treated with adefovir dipivoxil.The total course of treatment was 48 weeks.Results：After 12 weeks of treatment,HBV DNA negative conversion rate of the observation and control group were 54.5% and 20.8%,respectively（P0.05）.ALT normalization rate of the observation and control group were were 63.6% and 33.3%,respectively（P0.05）.After 24 weeks and 48 weeks of treatment,the above indexes showed no significant difference between the two groups.No significant adverse drug reactions were found in the two groups.Conclusion：On treatment of hepatitis B related cirrhosis with DNA positive,adefovir dipivoxil combined with lamivudine shows rapid onset,good effect in reducing viral load and good security.